60 Degrees Pharmaceuticals Inc (NASDAQ:SXTP) does about 308.49K shares in volume on a normal day but saw 233125 shares change hands in the recent trading day. The company now has a market cap of 3.04M USD. Its current market price is $1.32, marking an increase of 13.79% compared to the previous close of $1.16. The 52 week high reached by this stock is $18.36 whilst the lowest price level in 52 weeks is $0.70.
60 Degrees Pharmaceuticals Inc (SXTP) has a 20-day trading average at $1.3425 and the current price is -92.81% off the 52-week high compared with 88.17% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.0962 and its 200-day simple moving average is $2.1204. If we look at the stock’s price movements over the week, volatility stands at 14.30%, which increases to 19.59% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.51 to suggest the stock is neutral.
The consensus objective for the share price is $3.40, suggesting that the stock has a potential upside of 61.18% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is -1.60%, 20.46%, and -37.74% away from its SMA20, SMA50, and SMA200 respectively, with the SXTP price moving below the 50-day SMA on current market day. 60 Degrees Pharmaceuticals Inc (SXTP) stock is down -12.16% over the week and 44.44% over the past month. Its price is -89.38% year-to-date and -87.99% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.65 and -5.68 for whole year. Expected sales for next quarter are $300k, which analysts say will come at $622.5k for the current fiscal year and next year at $1.65M. In addition, estimates put the company’s current quarterly revenue at an average of $234k.
To reach the target analysts have set, the stock logically needs to grow 61.18 percent from here.
The company has a return on investment of -132.63% and return on equity of -124.71%. The beta has a value of 4.98. Price to sales ratio is 6.60.
